Valeant completes buyout of Coria Laboratories for $95 million

ALISO VIEJO, Calif. Valeant Pharmaceuticals International announced Thursday that it acquired Coria Laboratories, a drug company that focuses on skin medications.

Under the terms of the agreement, Valeant purchased all outstanding shares of Coria from parent company DFB Pharmaceuticals and other shareholders for $95 million.

Login or Register to post a comment.